Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 5NIH 2INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Melanoma 1103Carcinoma, Non-Small-Cell Lung 281Neoplasms 199Keratosis, Actinic 181Carcinoma, Renal Cell 162Skin Neoplasms 143Colorectal Neoplasms 142Neoplasm Metastasis 140Squamous Cell Carcinoma of Head and Neck 134Breast Neoplasms 118Ovarian Neoplasms 114Carcinoma, Basal Cell 97Stomach Neoplasms 94Pancreatic Neoplasms 93Lung Neoplasms 91Head and Neck Neoplasms 90Lymphoma, T-Cell, Cutaneous 88Uterine Cervical Neoplasms 75Triple Negative Breast Neoplasms 74Sarcoma 68Carcinoma, Hepatocellular 67Prostatic Neoplasms 65Uveal Melanoma 64Carcinoma, Merkel Cell 64Urinary Bladder Neoplasms 63Esophageal Neoplasms 61Carcinoma, Transitional Cell 57Lymphoma 55Endometrial Neoplasms 55Small Cell Lung Carcinoma 52

Interventions

denileukin diftitox 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Drug-Related Side Effects and Adverse Reactions × Dermatologic × Clear all
NCT06120712 2025-12-23

MIZAR-002

Shanghai Juncell Therapeutics

Phase 1/2 Completed
18 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡